Lutetium-177 Octreotate

Developed for: neuroendocrine neoplasm
Investigated by: Canadian Molecular Imaging Probe Consortium · Cancer Care Ontario · Ozmosis Research Inc. · University Health Network, Toronto

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT02743741	Jul 2016 → Jun 2026 overdue	neuroendocrine neoplasm	University Health Network, Toronto	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Lutetium-177 Octreotate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743741 ↗
Route	Intravenous	“by IV” NCT02743741 ↗